Inflammatory Bowel Disease Research Review, Issue 86
In this issue:
Intensified vs. standard infliximab induction for steroid-refractory acute severe UC
Harms with placebo in induction biologic/small molecule trials in IBD
Upadacitinib vs. vedolizumab, ustekinumab and tofacitinib for UC
Ustekinumab and adalimumab persistence for UC according to advanced therapy experience
Inflammatory eye disease: risk factor for microscopic colitis
Stricturing, penetrating complications and extraintestinal manifestations in IBD
Degree of bowel remission predicts phenotype progression in CD
Lymphoma risk in patients with IBD
Early ileal resection in CD: no association with severe long-term outcomes
Upadacitinib after tofacitinib for IBD
Expert contributor
Associate Professor Jonathan Segal
Jonathan Segal is an academic Gastroenterologist who completed his PhD and medical studies in London, United Kingdom before moving to Melbourne, Australia in 2022. He is vastly published in all areas of Inflammatory bowel disease with a specialist interest in the ileoanal pouch and the microbiome. He has recently been awarded an associate professorship at […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.